Immunovant, Inc.

NasdaqGS:IMVT Stock Report

Market Cap: US$3.5b

Immunovant Valuation

Is IMVT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IMVT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$27.35
Fair Value
25.4% undervalued intrinsic discount
12
Number of Analysts

Below Fair Value: IMVT ($20.41) is trading below our estimate of fair value ($27.35)

Significantly Below Fair Value: IMVT is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IMVT?

Key metric: As IMVT is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for IMVT. This is calculated by dividing IMVT's market cap by their current book value.
What is IMVT's PB Ratio?
PB Ratio9.8x
BookUS$352.62m
Market CapUS$3.46b

Price to Book Ratio vs Peers

How does IMVT's PB Ratio compare to its peers?

The above table shows the PB ratio for IMVT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average17.7x
VKTX Viking Therapeutics
4.1x0.9%US$3.5b
CRNX Crinetics Pharmaceuticals
4.1x28.4%US$3.6b
APLS Apellis Pharmaceuticals
15.4x61.3%US$3.8b
SRRK Scholar Rock Holding
47.2x55.9%US$3.8b
IMVT Immunovant
9.8x5.1%US$3.5b

Price-To-Book vs Peers: IMVT is good value based on its Price-To-Book Ratio (9.8x) compared to the peer average (17.7x).

Price to Book Ratio vs Industry

How does IMVT's PB Ratio compare vs other companies in the US Biotechs Industry?

72 CompaniesPrice / BookEstimated GrowthMarket Cap
SLRN Acelyrin
0.4x16.8%US$190.62m
LYEL Lyell Immunopharma
0.3x-13.7%US$172.67m
NKTX Nkarta
0.4x-8.3%US$165.13m
FATE Fate Therapeutics
0.4x-4.1%US$159.45m
IMVT 9.8xIndustry Avg. 1.7xNo. of Companies78PB01.63.24.86.48+
72 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: IMVT is expensive based on its Price-To-Book Ratio (9.8x) compared to the US Biotechs industry average (1.7x).

Price to Book Ratio vs Fair Ratio

What is IMVT's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IMVT PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio9.8x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate IMVT's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IMVT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$20.41
US$50.08
+145.4%
11.0%US$58.00US$41.00n/a12
Feb ’26US$21.74
US$50.17
+130.8%
10.8%US$58.00US$41.00n/a12
Jan ’26US$24.77
US$49.77
+100.9%
11.0%US$58.00US$41.00n/a13
Dec ’25US$28.20
US$48.93
+73.5%
12.4%US$58.00US$36.00n/a15
Nov ’25US$29.39
US$48.60
+65.4%
12.0%US$60.00US$36.00n/a15
Oct ’25US$28.45
US$49.07
+72.5%
10.0%US$60.00US$41.00n/a14
Sep ’25US$30.90
US$48.43
+56.7%
8.1%US$57.00US$41.00n/a14
Aug ’25US$28.87
US$49.14
+70.2%
7.4%US$57.00US$42.00n/a14
Jul ’25US$27.51
US$49.14
+78.6%
7.4%US$57.00US$42.00n/a14
Jun ’25US$25.39
US$50.43
+98.6%
6.4%US$57.00US$44.00n/a14
May ’25US$28.52
US$50.87
+78.4%
7.6%US$57.00US$40.00n/a15
Apr ’25US$31.61
US$50.65
+60.2%
7.3%US$57.00US$40.00n/a17
Mar ’25US$35.30
US$50.73
+43.7%
7.7%US$57.00US$40.00n/a15
Feb ’25US$36.07
US$50.23
+39.3%
8.0%US$57.00US$40.00US$21.7413
Jan ’25US$42.13
US$50.23
+19.2%
8.0%US$57.00US$40.00US$24.7713
Dec ’24US$40.55
US$49.33
+21.7%
8.7%US$57.00US$40.00US$28.2012
Nov ’24US$33.47
US$48.92
+46.2%
9.1%US$57.00US$40.00US$29.3912
Oct ’24US$38.39
US$40.67
+5.9%
27.0%US$54.00US$18.00US$28.4512
Sep ’24US$23.99
US$29.92
+24.7%
13.8%US$34.00US$18.00US$30.9012
Aug ’24US$23.07
US$29.54
+28.0%
12.9%US$34.00US$18.00US$28.8713
Jul ’24US$18.97
US$28.23
+48.8%
12.4%US$32.00US$18.00US$27.5113
Jun ’24US$20.68
US$26.50
+28.1%
26.7%US$32.00US$4.00US$25.3914
May ’24US$17.62
US$24.86
+41.1%
27.7%US$31.00US$4.00US$28.5214
Apr ’24US$15.51
US$24.50
+58.0%
30.1%US$31.00US$4.00US$31.6112
Mar ’24US$17.50
US$23.30
+33.1%
33.9%US$31.00US$4.00US$35.3010
Feb ’24US$18.20
US$18.25
+0.3%
53.1%US$30.00US$4.00US$36.078
Analyst Price Target
Consensus Narrative from 12 Analysts
US$50.08
Fair Value
59.2% undervalued intrinsic discount
12
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 01:14
End of Day Share Price 2025/02/07 00:00
Earnings2024/12/31
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Immunovant, Inc. is covered by 17 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Jason Matthew GerberryBofA Global Research
Louise ChenCantor Fitzgerald & Co.